ZYXI

Zynex Inc

Add to Watchlist

Advanced Chart

2.310

-0.04(-1.702%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.3993

Open

2.370

VWAP

2.33

Vol

70.11K

Mkt Cap

69.85M

Low

2.260

Amount

163.43K

EV/EBITDA(TTM)

Total Shares

31.78M

105.86M

EV/OCF(TTM)

705.71

P/S(TTM)

0.43

Zynex, Inc. is a medical technology company specialized in the manufacturing and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring. The Company’s devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Company’s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave, M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Private Labeled Rehabilitation Products, which include Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces, Bracing (Knee and Wrist), and Dynacomp, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

32.97M

-28.29%

29.59M

-40.78%

27.38M

-45.12%

Estimates Revision

The market is revising Downward the revenue expectations for Zynex, Inc. (ZYXI) for FY2025, with the revenue forecasts being adjusted by -8.18% over the past three months. During the same period, the stock price has changed by 8.45%.

Revenue Estimates for FY2025

Revise Downward

-8.18%

In Past 3 Month

Stock Price

Go Up

+8.45%

In Past 3 Month

2 Analyst Rating

159.74% Upside

Wall Street analysts forecast ZYXI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYXI is 6.00 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

159.74% Upside

Current: 2.310

Low

4.00

Averages

6.00

High

8.00

159.74% Upside

Current: 2.310

Low

4.00

Averages

6.00

High

8.00

RBC Capital

Sector Perform

downgrade

$4 -> $3

2025-07-15

New

Reason

RBC Capital

Price Target

$4 -> $3

2025-07-15

New

downgrade

Sector Perform

Reason

RBC Capital lowered the firm's price target on Zynex to $3 from $4 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 results for MedTech names. Based on the firm's intra-quarter diligence with key opinion leaders and company management / investor discussions, there is a high level of interest in MedTech and multiple opportunities across the sector, the analyst tells investors in a research note. Regarding the company however, the firm notes that sentiment on the stock is quite negative given its Q1 miss and no guidance issued for 2025.

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$17 → $15

2025-03-12

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$17 → $15

2025-03-12

Maintains

Strong Buy

Reason

Ladenburg Thalmann

Jeffrey Cohen

Strong Buy

Hold

Downgrades

n/a

2025-03-12

Reason

Ladenburg Thalmann

Jeffrey Cohen

Price Target

n/a

2025-03-12

Downgrades

Strong Buy

Hold

Reason

Ladenburg downgraded Zynex to Neutral from Buy without a price target saying the company continues to adjust operationally amid revenue pressure.

RBC Capital

Shagun Singh

Buy

Hold

Downgrades

$11 → $5.5

2025-03-12

Reason

RBC Capital

Shagun Singh

Price Target

$11 → $5.5

2025-03-12

Downgrades

Buy

Hold

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$17

2024-12-06

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$17

2024-12-06

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$16 → $17

2024-10-25

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$16 → $17

2024-10-25

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Zynex Inc (ZYXI.O) is -3.81, compared to its 5-year average forward P/E of 25.55. For a more detailed relative valuation and DCF analysis to assess Zynex Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

25.55

Current PE

-3.81

Overvalued PE

40.02

Undervalued PE

11.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

14.00

Current EV/EBITDA

-7.41

Overvalued EV/EBITDA

23.26

Undervalued EV/EBITDA

4.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

2.24

Current PS

0.56

Overvalued PS

3.47

Undervalued PS

1.01

Financials

Annual

Quarterly

FY2025Q1

YoY :

-42.88%

26.58M

Total Revenue

FY2025Q1

YoY :

-2594.67%

-13.10M

Operating Profit

FY2025Q1

YoY :

-104060.00%

-10.40M

Net Income after Tax

FY2025Q1

-0.33

EPS - Diluted

FY2025Q1

YoY :

-657.23%

-10.67M

Free Cash Flow

FY2025Q1

YoY :

-14.38%

68.51

Gross Profit Margin - %

FY2025Q1

YoY :

-102.93%

-0.26

FCF Margin - %

FY2025Q1

YoY :

-195700.00%

-39.12

Net Margin - %

FY2025Q1

YoY :

-100.00%

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

148.3K

USD

6-9

Months

419.3K

USD

0-12

Months

35.5K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

148.3K

USD

6-9

Months

419.3K

USD

0-12

Months

35.5K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ZYXI News & Events

Events Timeline

2025-07-02 (ET)

2025-07-02

17:17:55

Zynex notified by Tricare that temporary payment suspension will continue

2025-06-30 (ET)

2025-06-30

09:16:21

Zynex names Steven Dyson as new CEO

2025-06-25 (ET)

2025-06-25

09:16:47

Zynex awarded noninvasive sepsis monitor patent in the UK

News

7.0

07-10Globenewswire

ZYNEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

7.0

07-03Globenewswire

Johnson Fistel, PLLP Investigates Telephone and Data Systems, Fluence Energy, The Bancorp, and Zynex on Behalf of Long-Term Shareholders

7.0

07-02Newsfilter

Tricare Temporary Payment Suspension Update